Evidence map›Paper›PMID 29449543›Full record

ArticleBlood cancer journal2018

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Natasha Szuber, Christy M Finke, Terra L Lasho, Michelle A Elliott, Curtis A Hanson, Animesh Pardanani, Ayalew Tefferi

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  2. Haematologica · 2025
    Article
  3. Article
  4. Expanding the Spectrum ofJournal of clinical medicine · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. The spectrum of Ph-negative disease: CNL and CSF3R-related disorders.Hematology. American Society of Hematology. Education Program · 2024
    Review
  9. Review
  10. Review
  11. Archives of medical science : AMS · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Natasha SzuberDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Christy M FinkeDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Terra L LashoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Michelle A ElliottDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Curtis A HansonDivision of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Animesh PardananiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Ayalew TefferiDivision of Hematology, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Neutrophilic, ChronicModels, BiologicalAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedMutationReceptors, Colony-Stimulating FactorRisk AssessmentSurvival RateCSF3R protein, humanReceptors, Colony-Stimulating Factor

Identifiers

PMID29449543
PMCPMC5814430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.